0
0
Read Time:10 Second
Aurobindo Pharma subsidiary CuraTeQ Biologics and U.S. firm BioFactura terminated agreement relating to BFI751, a proposed biosimilar to Janssen Biotech’s Stelara (Ustekinumab). The decision is aligned with CuraTeQ’s strategic portfolio prioritisation…
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %